ANXA5 and osteosarcoma: In addition, flow-cytometry analyses of apoptosis by Annexin-V staining shows that an overnight InhiTinib treatment at a dose of 3.10 μM (the IC100 dose for EL4), in contrast to DMSO, promotes death of murine A20 B-cell lymphoma, B16 melanoma, P815 mastocytoma, human breast cancer cell lines BT549 and MDA-MB-231, U87 glioblastoma, and U-2 OS osteosarcoma (Figure 2C).